Want to see IN:JAGSNPHARM full AI Analyst Report?
Top Page
Jagsonpal Pharmaceuticals Ltd.
(JAGSNPHARM)
Select Model
Select Model
Rating:78Outperform
Price Target:
₹272.00
▲(40.57% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by strong financial quality—very conservative leverage, healthy margins, and solid recent cash conversion—supported by a clear technical uptrend. Offsetting these positives are a higher valuation (P/E ~33.9 with a modest ~1.1% dividend yield) and some recent earnings volatility (net income down in 2026 vs. 2025 despite strong revenue growth).
Positive Factors
Very Low Leverage
Minimal debt reduces financial risk and interest burden, giving Jagsonpal flexibility to fund product development, sales expansion, and working-capital needs without materially increasing balance-sheet pressure.
Negative Factors
Earnings Volatility
Falling earnings despite stronger reported revenue suggests inconsistent conversion of growth into profit, making future profitability less predictable and potentially limiting confidence in the durability of recent expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Minimal debt reduces financial risk and interest burden, giving Jagsonpal flexibility to fund product development, sales expansion, and working-capital needs without materially increasing balance-sheet pressure.
Read all positive factors
Jagsonpal Pharmaceuticals Ltd. (JAGSNPHARM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹15.39B
Dividend Yield1.71%
Average Volume (3M)8.72K
Price to Earnings (P/E)34.2
Beta (1Y)0.91
Revenue Growth3.87%
EPS Growth-25.38%
CountryIN
Employees1,305
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)6.80
Shares Outstanding65,957,420
10 Day Avg. Volume9,920
30 Day Avg. Volume8,723
Financial Highlights & Ratios
PEG Ratio-1.29
Price to Book (P/B)4.53
Price to Sales (P/S)4.35
P/FCF Ratio26.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Jagsonpal Pharmaceuticals Ltd. Business Overview & Revenue Model
Company Description
Jagsonpal Pharmaceuticals Limited, an Indian company founded in 1964 and based in New Delhi, specializes in the development and manufacturing of both bulk active pharmaceutical ingredients and diverse medicinal formulations. Its product portfolio ...
How the Company Makes Money
Jagsonpal Pharmaceuticals primarily makes money by selling pharmaceutical formulations (finished dosage medicines) in the Indian market. Revenue is generated through (1) domestic sales of branded formulations to channel partners such as stockists/...
Jagsonpal Pharmaceuticals Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
87
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.94B | 2.87B | 2.69B | 2.09B | 2.37B | 2.18B |
| Gross Profit | 1.63B | 1.83B | 1.72B | 652.59M | 1.44B | 1.28B |
| EBITDA | 681.92M | 679.90M | 510.71M | 323.46M | 363.96M | 284.53M |
| Net Income | 454.76M | 430.82M | 553.61M | 224.63M | 267.21M | 188.55M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 3.17B | 2.78B | 2.17B | 1.95B | 1.68B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.06B | 1.29B | 1.48B | 1.15B | 472.77M |
| Total Debt | 0.00 | 81.65M | 92.39M | 89.41M | 60.01M | 52.47M |
| Total Liabilities | -2.76B | 405.05M | 383.10M | 296.76M | 360.56M | 375.99M |
| Stockholders Equity | 2.76B | 2.76B | 2.40B | 1.87B | 1.59B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 245.77M | 466.64M | 549.52M | 349.18M | 463.37M | 51.31M |
| Operating Cash Flow | 246.75M | 468.12M | 553.00M | 351.66M | 466.54M | 55.98M |
| Investing Cash Flow | -82.07M | -356.49M | -451.47M | -245.48M | -576.71M | -257.79M |
| Financing Cash Flow | -148.90M | -121.49M | -116.98M | -89.11M | -4.57M | -175.52M |
Jagsonpal Pharmaceuticals Ltd. Technical Analysis
Neutral
193.50
Price Trends
229.20
Positive
218.43
Positive
200.78
Positive
Market Momentum
2.18
Positive
50.66
Neutral
22.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JAGSNPHARM, the sentiment is Neutral. The current price of 193.5 is below the 20-day moving average (MA) of 234.51, below the 50-day MA of 229.20, and below the 200-day MA of 200.78, indicating a neutral trend. The MACD of 2.18 indicates Positive momentum. The RSI at 50.66 is Neutral, neither overbought nor oversold. The STOCH value of 22.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:JAGSNPHARM.
Jagsonpal Pharmaceuticals Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | ₹21.82B | 18.60 | ― | 0.62% | 20.87% | 116.29% | |
78 Outperform | ₹15.39B | 34.25 | ― | 1.71% | 3.87% | -25.38% | |
78 Outperform | ₹12.52B | 12.95 | ― | 0.29% | 10.20% | 11.70% | |
70 Outperform | ₹18.34B | 21.38 | ― | 0.51% | 0.44% | 48.60% | |
69 Neutral | ₹25.43B | 71.38 | ― | ― | 43.77% | 80.23% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₹33.58B | 57.04 | ― | 1.14% | 113.34% | -80.12% |
* General Sector Average
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
233.40
-12.63
-5.13%
IN:INDSWFTLAB
Ind-Swift Laboratories Ltd.
386.10
278.72
259.56%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
625.05
72.52
13.12%
IN:SAKAR
Sakar Healthcare Ltd
1,158.55
816.70
238.91%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
19.51
1.68
9.42%
IN:VENUSREM
Venus Remedies Limited
1,632.25
1,183.09
263.40%
Jagsonpal Pharmaceuticals Ltd. Corporate Events
Jagsonpal Pharma Publishes Q1 FY27 Earnings Call Transcript
Aug 4, 2026
Jagsonpal Pharmaceuticals Limited announced that it has released the official transcript of its Q1 FY27 earnings conference call, which was held on July 30, 2026, to discuss the company’s financial results for the quarter. The transcript, pr...
Jagsonpal Pharmaceuticals Publishes Q1 FY27 Earnings Call Transcript
Aug 4, 2026
Jagsonpal Pharmaceuticals Limited has released the transcript of its Q1 FY27 earnings conference call, which was held on July 30, 2026, to discuss its financial results for the quarter. The document, filed with both the BSE and NSE under regulator...
Jagsonpal Pharma Grants 120,000 ESOPs Under 2022 Plan
Jul 29, 2026
Jagsonpal Pharmaceuticals Ltd. has approved the grant of 120,000 employee stock options under its 2022 ESOP plan at an exercise price of Rs 179.25 per option. The options are convertible into an equal number of equity shares with a face value of R...
Jagsonpal Pharma Secures Controlling Stake in Aequitas Healthcare
Jul 7, 2026
Jagsonpal Pharmaceuticals Limited has advanced its expansion strategy in the Indian healthcare market by acquiring a controlling equity stake in Aequitas Healthcare Private Limited. The listed pharmaceutical company, traded on BSE and NSE as JAGSN...
Jagsonpal Pharma Promoters Report No Share Encumbrances for FY 2026
Jun 30, 2026
Jagsonpal Pharmaceuticals Ltd., a listed Indian drug maker traded on BSE and NSE, has disclosed annual promoter shareholding details under the Securities and Exchange Board of India’s takeover regulations for the year ended March 31, 2026. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.